The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours. The information gathered from this survey will be used in order to prepare a patient evidence submission to
OTTAWA, January 14, 2013 – According to the results of a new survey completed by over 1,070 members of the Canadian Pharmacists Association, Canadian Medical Association, and Canadian Society of Hospital Pharmacists in October 2012, drug shortages clearly remain a problem for Canada’s health system. The survey confirms that the health and well?being of patients is
Provinces are fifth and sixth in Canada to reimburse new metastatic prostate cancer treatment Toronto, ON (May 16, 2012) – Men living with metastatic prostate cancer in Nova Scotia and Newfoundland and Labrador now have access to a new treatment option, as these provinces have made the decision to include ZYTIGA® (abiraterone acetate) on their
First Oral Treatment for Metastatic Prostate Cancer That Inhibits Androgen Production at All Three Sources Toronto, ON, July 28, 2011– Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer. ZYTIGA™ is indicated with prednisone for the
Patients with advanced prostate cancer gain access to first-in-class treatment OTTAWA, April 25, 2012 /CNW/ – Canadian Cancer Survivor Network (CCSN) is today congratulating the Ontario government for providing access to XGEVA® (denosumab) for the prevention of debilitating bone complications, known as skeletal-related events (SREs), in men with advanced prostate cancer which has spread to the bone.
Coverage Will Eliminate Financial Burdens For Patients, Families (April 19, 2012) Premier Greg Selinger today announced the government will help support cancer patients and their families by making oral cancer drugs free for Manitobans, eliminating deductibles and covering the cost of necessary support drugs that patients may need during their treatment. “This budget will help